Last reviewed · How we verify
Low dose levetiracetam — Competitive Intelligence Brief
marketed
Antiepileptic agent
SV2A (synaptic vesicle protein 2A)
Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Low dose levetiracetam (Low dose levetiracetam) — Richard H. Haas. Low-dose levetiracetam reduces neuronal excitability by binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Low dose levetiracetam TARGET | Low dose levetiracetam | Richard H. Haas | marketed | Antiepileptic agent | SV2A (synaptic vesicle protein 2A) | |
| Keppra | levetiracetam | Generic (originally UCB Pharma) | marketed | Antiepileptic agent | Synaptic vesicle protein SV2A | 1999-11-30 |
| Low dose zonisamide | Low dose zonisamide | Mario Negri Institute for Pharmacological Research | marketed | Anticonvulsant / Antiepileptic agent | Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase | |
| Topiramate-Implant | Topiramate-Implant | University of Sao Paulo | marketed | Anticonvulsant / Antiepileptic agent | GABA-A receptor, sodium channels, glutamate receptors | |
| LEV | LEV | GlaxoSmithKline | marketed | Antiepileptic agent | SV2A (synaptic vesicle glycoprotein 2A) | |
| Qudexy XR | Qudexy XR | Upsher-Smith Laboratories | marketed | Anticonvulsant / Antiepileptic agent | GABA-A receptor; voltage-gated sodium channels | |
| Lacosamide - rapid titration 1 | Lacosamide - rapid titration 1 | Seoul National University Hospital | marketed | Antiepileptic agent (sodium channel modulator) | Voltage-gated sodium channels (slow inactivation enhancer) |
Recent regulatory actions (last 90 days)
- — Keppra · FDA · approved · US · Generic (originally UCB Pharma)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Keppra · 8163306 · Formulation · US
- — Keppra · 8431156 · Formulation · US
- — Keppra · 8470367 · Formulation · US
- — Keppra · 7858122 · Formulation · US
- — Keppra · 8802142 · Formulation · US
- — Keppra · 8802142*PED · Compound · US
- — Keppra · 11160786 · Formulation · US
- — Keppra · 9669009 · Method of Use · US
- — Keppra · 9339489 · Formulation · US
Sponsor landscape (Antiepileptic agent class)
- Children's Hospital of Fudan University · 1 drug in this class
- Generic (originally UCB Pharma) · 1 drug in this class
- GlaxoSmithKline · 1 drug in this class
- Hospices Civils de Lyon · 1 drug in this class
- Mario Negri Institute for Pharmacological Research · 1 drug in this class
- Richard H. Haas · 1 drug in this class
- ayesha tariq · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Low dose levetiracetam CI watch — RSS
- Low dose levetiracetam CI watch — Atom
- Low dose levetiracetam CI watch — JSON
- Low dose levetiracetam alone — RSS
- Whole Antiepileptic agent class — RSS
Cite this brief
Drug Landscape (2026). Low dose levetiracetam — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-levetiracetam. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab